In this article on product hopping, we explain that, considering the potential for significant consumer benefits from even small changes in product design, coupled with antitrust agencies and courts being ill-equipped to displace the judgments of consumers (and, with regard to drugs, their doctors) about the value of a new product design, product hopping should be per se lawful absent objective evidence that Product B is a sham innovation with zero or negative consumer welfare effects.